



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

12th November, 2020

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: 532878

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: ALPA

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

This is with reference to our letter dated 02nd November, 2020 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 4.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1. Approval of the Un-Audited Standalone & Consolidated Financial Results of the Company for Quarter and Half Year ended on 30th September, 2020 with Limited Review Report from the Statutory Auditor of the Company.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

For ALPA LABORATORIES LIMITED

Mahendra

Mahendra Singh Chawla
Director
DIN-00362058





**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE
QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE
SEBI LODR REGULATIONS, 2015**

To the Board of Directors of ALPA LABORATORIES LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **September 30, 2020**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of

ANURADHA RATNAPARKHI & ASSOCIATES.

Chartered Accountants

Firm Registration No.023451C

ANURADHA RATNAPARKHI

Proprietor

Membership Number:075412

UDIN-20075412AAAAAR5575

Place: Indore

Date: 12th November, 2020

ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 30th September 2020

(Rs. in lacs except EPS)

I. Statement of Profit and Loss - Standalone and Consolidated

Particular	Standalone Results					
	Quarter Ended			Half Year Ended		Year Ended
	30-Sep-20	30-Jun-20	30-Sep-19	30-Sep-20	30-Sep-19	31-Mar-20
	Unaudited					Audited
1. Income						
a) Revenue from operations	2,310.79	1,629.46	2,351.28	3,940.25	4,367.99	8,596.91
b) Other Income	86.65	172.49	35.33	259.15	103.27	296.67
1. Total income from operations (net) (a+b)	2,397.44	1,801.95	2,386.60	4,199.40	4,471.25	8,893.58
2. Expenses						
a) Cost of materials consumed	1,671.03	769.88	1,494.56	2,440.91	2,815.45	4,948.01
b) Purchases of stock-in-trade	215.09	65.05	44.21	280.15	94.41	193.83
c) Changes in inventories of finished products, work in progress and stock in trade	(432.27)	48.20	19.47	(384.07)	(101.80)	(42.41)
d) Employee benefit expenses	277.65	249.05	279.69	526.69	561.03	1,182.43
e) Finance costs	3.49	2.28	4.49	5.77	13.45	19.94
f) Depreciation and amortization expenses	28.97	28.11	27.26	57.08	52.35	114.20
g) Other expenses						
Manufacturing & Operating	138.14	80.80	116.30	218.94	215.12	427.09
Others	266.53	235.57	302.79	502.10	545.83	1,542.76
Total expenses	2,168.63	1,478.95	2,288.77	3,647.57	4,195.84	8,385.85
3. Profit/(Loss) before exceptional items and tax (1-2)	228.82	323.01	97.83	551.82	275.41	507.73
4. Exceptional Items	-	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	228.82	323.01	97.83	551.82	275.41	507.73
6. Tax (Expenses)/ Benefit						
Current tax	-	-	-	-	-	(190.00)
Deffered tax	-	-	-	-	-	75.48
Tax Related to Earlier Years	-	-	-	-	-	14.60
7. Profit/ Loss(-) for the period (5-/+6)	228.82	323.01	97.83	551.82	275.41	407.81
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	0.54	0.51	0.30	1.04	1.67	2.49
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.54	0.51	0.30	1.04	1.67	2.49
9. Total comprehensive income for the period (7+8)	229.35	323.51	98.14	552.87	277.09	410.30
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)	-	-	-	-	-	8,918.90
12. Debenture Redemption Reserve	-	-	-	-	-	-
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	1.09	1.54	0.47	2.63	1.32	1.95



For Alpa Laboratories Ltd.

 Mahendra Singh Chawla
 Director
 DIN-00362058




**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED
QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF
THE SEBI LODR REGULATIONS, 2015**

To the Board of Directors of ALPA LABORATORIES LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **September 30, 2020**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of
ANURADHA RATNAPARKHI & ASSOCIATES.

Chartered Accountants
Firm Registration No.023451C


ANURADHA RATNAPARKHI
Proprietor

Membership Number: 075412
UDIN-20075412AAAAAS1495

Place: Indore

Date: 12th November, 2020

ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 30th September 2020

(Rs. In lacs except EPS)

Particular	Consolidated Results					
	Quarter Ended			Half Year Ended		Year Ended
	30-Sep-20	30-Jun-20	30-Sep-19	30-Sep-20	30-Sep-19	31-Mar-20
	Unaudited					Audited
1. Income						
a) Revenue from operations	2,310.79	1,629.46	2,351.28	3,940.25	4,367.99	8,596.91
b) Other Income	89.93	170.60	26.72	260.52	97.30	291.24
1. Total income from operations (net) (a+b)	2,400.72	1,800.06	2,377.99	4,200.77	4,465.28	8,888.15
2. Expenses						
a) Cost of materials consumed	1,671.03	769.88	1,494.56	2,440.91	2,815.45	4,948.01
b) Purchases of stock-in-trade	215.09	65.05	44.21	280.15	94.41	193.83
c) Changes in inventories of finished products, work in progress and stock in trade	(432.27)	48.20	19.47	(384.07)	(101.80)	(42.41)
d) Employee benefit expenses	277.65	249.05	279.69	526.69	561.03	1,182.43
e) Finance costs	2.86	2.28	4.49	5.14	13.45	19.62
f) Depreciation and amortization expenses	28.97	28.11	77.82	57.08	153.48	316.45
g) Other expenses						
Manufacturing & Operating	138.14	80.80	116.30	218.94	215.12	427.09
Others	266.53	235.57	302.81	502.11	554.26	1,552.38
Total expenses	2,168.01	1,478.95	2,339.35	3,646.95	4,305.40	8,597.40
3. Profit/(Loss) before exceptional items and tax (1-2)	232.71	321.11	38.65	553.82	159.89	290.75
4. Exceptional Items	-	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	232.71	321.11	38.65	553.82	159.89	290.75
6. Tax (Expenses)/ Benefit						
Current tax	-	-	-	-	-	(190.00)
Deferred tax	-	-	-	-	-	75.48
Tax Related to Earlier Years	-	0.15	-	0.15	-	9.11
7. Profit/ Loss(-) for the period (5-/+6)	232.71	321.25	38.65	553.96	159.89	185.34
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	0.54	0.51	0.30	1.04	1.67	2.49
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.54	0.51	0.30	1.04	1.67	2.49
9. Total comprehensive income for the period (7+8)	233.25	321.76	38.95	555.01	161.56	187.82
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)	-	-	-	-	-	7,933.20
12. Debenture Redemption Reserve	-	-	-	-	-	-
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	1.11	1.53	0.19	2.64	0.77	0.89

Notes -

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- Covid-19 pandemic has been rapidly spreading throughout the world, including India. Government in India has taken significant measures to curb the spread of the virus including imposing mandatory lockdowns and restrictions in activities. The Company is monitoring the situation closely taking into account directives from the Governments. Management believes that it has taken into account all the possible impacts of known events arising from COVID-19 pandemic and the resultant lockdowns in the preparation of the financial statements including but not limited to its assessment of Company's liquidity and going concern, recoverable values of its property, plant and equipment, intangible assets, intangible assets under development and the net realisable values of other assets. However, given the effect of these lockdowns on the overall economic activity the assessment of COVID-19 on the abovementioned financial statement captions is subject to significant estimation uncertainties given its nature and duration and, accordingly, the actual impacts in future may be different from those estimated as at the date of approval of these financial results. The Company will continue to monitor any material changes to future economic conditions and consequential impact on its financial results.



For Alpa Laboratories Ltd.

Mahendra
Mahendra Singh Chawla
Director
DIN-00362058

ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 30th September 2020

(Rs. in lacs except EPS)

II. Statement of Assets and Liabilities - Standalone and Consolidated

Particulars	Standalone Results		Consolidated Results	
	30-Sep-20	31-Mar-20	30-Sep-20	31-Mar-20
	Unaudited	Audited	Unaudited	Audited
ASSETS				
Non-current assets				
(a) Property Plant and Equipment	638.64	641.64	638.64	641.64
(b) Capital Work-in-progress	81.94	81.27	81.94	81.27
(c) Investments in subsidiaries, associates and joint venture	1,105.44	1,102.45	-	-
(d) Intangible Assets	6.13	-	6.13	-
(e) Financial Assets				
(i) Investment	1,600.32	1,728.71	1,600.32	1,728.71
(ii) Other Financial Assets	326.34	44.63	326.34	44.63
(f) Deferred tax assets (net)	92.58	92.58	92.58	92.58
Sub-total - Non-current assets	3,851.39	3,691.29	2,745.95	2,588.84
Current Assets				
(a) Inventories	1,723.95	1,255.05	1,723.95	1,255.05
(b) Financial Assets				
(i) Investment	4,594.69	3,929.58	4,594.69	3,929.58
(ii) Trade receivables	2,271.15	2,458.96	2,271.15	2,458.96
(iii) Cash and Cash Equivalents	262.45	472.03	264.61	497.47
(iv) Bank Balances other than (iii) above	139.50	119.50	139.50	119.50
(v) Short term loans & advances	4.39	29.69	77.48	98.87
(vi) Others	146.75	237.02	146.75	237.02
(c) Current Tax Assets (Net)	60.00	-	60.00	-
(d) Other current assets	1,167.34	927.17	1,189.31	949.83
Sub-total - Current assets	10,370.23	9,429.00	10,467.45	9,546.28
TOTAL - ASSETS	14,221.61	13,120.29	13,213.39	12,135.12
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	2,104.06	2,104.06	2,104.06	2,104.06
(b) Other Equity	9,471.77	8,918.90	8,488.06	7,933.20
Sub-total - Equity	11,575.83	11,022.96	10,592.12	10,037.26
Liabilities				
Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	32.92	19.20	7.55	19.20
Sub-total - Non-current liabilities	32.92	19.20	7.55	19.20
Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	-	-	-	-
(ii) Trade Payables	1,706.99	1,371.68	1,707.63	1,372.32
(iii) Other Financial Liabilities	162.07	150.39	162.07	150.09
(b) Provisions	278.14	232.25	278.35	232.47
(c) Current tax Liabilities (Net)		65.00		65.00
(d) Other Current Liabilities	465.67	258.82	465.67	258.79
Sub-total - Current liabilities	2,612.86	2,078.13	2,613.72	2,078.66
TOTAL - EQUITY AND LIABILITIES	14,221.61	13,120.29	13,213.39	12,135.12



For Alpa Laboratories Ltd.

Mahendra
 Mahendra Singh Chawla
 Director
 DIN-00362058

ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)


453446

Financial Results for Quarter ended 30th September 2020

(Rs. in lacs except EPS)

III. Statement of Cash Flows - Standalone and Consolidated

Particular	For the Half Year Ended on 30-09-2020	
	Standalone	Consolidated
<u>CASH FLOW FROM OPERATING ACTIVITIES:</u>		
Profit / (loss) before tax	551.82	553.82
Adjustments for:		
Depreciation and amortization	57.08	57.08
Finance cost	5.77	5.14
Dividend income	(12.25)	(12.25)
Interest income	(19.33)	(19.33)
Net (Gain)/Loss on sale / fair valuation of investments through profit and loss	(221.67)	(218.68)
Bad debts / assets written off	80.00	80.00
Other Comprehensive Income (Non Cash)	1.04	1.04
(Profit)/ loss on sale of Fixed Assets (net)	0.26	0.26
Operating profit before working capital changes	442.73	447.09
Changes in Operating assets and liabilities:		
Decrease/ (Increase) in Trade Receivable/Other Receivables	(298.51)	(301.72)
Decrease/ (Increase) in Inventories	(468.90)	(468.90)
Increase/ (Decrease) in Provisions	45.89	45.89
Increase/ (Decrease) in Trade payable/Current Liabilities	553.85	554.17
Net Cash Flow from Operating Activities	275.06	276.53
Income taxes paid	125.00	125.00
Net Cash Flow from Operating Activities Before Exceptional Items	150.06	151.53
Exceptional Items	-	-
Net Cash Flow from Operating Activities After Exceptional Items (I)	150.06	151.53
<u>CASH FLOW FROM INVESTING ACTIVITIES:</u>		
Proceeds from/(Payments for):		
Dividend received from others	12.25	12.25
Interest Received	19.33	19.33
Property, plant and equipment	(61.14)	(61.14)
Purchase of investment	(446.44)	(446.44)
Investment in subsidiaries/ Joint Venture	128.40	128.40
Net Cash Flow from Investing Activities (II)	(347.60)	(347.60)
<u>CASH FLOW FROM FINANCING ACTIVITIES:</u>		
Proceeds from/(payment to):		
Long Term Borrowings	13.73	(11.65)
Short Term Borrowings	-	-
Interest Paid	(5.77)	(5.14)
Net Cash Flow from Financing Activities (III)	7.95	(16.79)
Net Increase/(Decrease) In Cash and Cash Equivalents (I + II + III)	(189.58)	(212.86)
Cash and Cash Equivalents as at the beginning of the year	591.53	616.97
Cash and Cash Equivalents as at the end of the year	401.95	404.11
Cash and Cash Equivalents Comprise of:		
Cash and Bank Balances	262.45	264.61
Fixed Deposits with Banks	139.50	139.50
Total Cash & Cash Equivalents	401.95	404.11



For Alpa Laboratories Ltd.

Mahendra

Mahendra Singh Chawla
Director
DIN-00362058